Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa M Hess

Showing results (101-110 of 102) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 102 results.
Current Medical Research and Opinion|January 30, 2026
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysisCatherine C Coombs, Jennifer A Woyach, Jennifer R Brown, et al.
Journal of Geriatric Oncology|June 17, 2026
Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi settingPaolo Ghia, Davide Rossi, Emmanuelle Ferrant, et al.
Pageof 11

Showing results (101-110 of 102) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 102 results.
Current Medical Research and Opinion|January 30, 2026
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysisCatherine C Coombs, Jennifer A Woyach, Jennifer R Brown, et al.
Journal of Geriatric Oncology|June 17, 2026
Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi settingPaolo Ghia, Davide Rossi, Emmanuelle Ferrant, et al.
Pageof 11